IP Library › Granted Patent US 7,396,820
Granted Patent B2
US 7,396,820 · App. 10/800,407 · Granted Jul 8, 2008

Anthelmintic formulations

Assignees: Virbac Corporation; The Hartz Mountain Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,396,820
App. No.
10/800,407
Granted
Jul 8, 2008
Kind
B2
Abstract

The present invention provides a method for preparing a pharmaceutical formulation containing ivermectin and a method and composition that can contain ivermectin plus hexahydropyrazinoisoquinolines, tetrahydropyrimidines and benzimidazoles or febantel. Examples of hexahydropyrazinoisoquinolines, tetrahydropyrimidines and benzimidazoles include praziquantel, pyrantel pamoate and fenbendazole, respectively. A pharmaceutical formulation is provided for use in the treatment of helminthiasis of mammals, and particularly tapeworm, hookworm, roundworm, whipworm and heartworm of domestic animals and farm animals. The present invention also provides a method of treating helminthiasis in mammals, which method comprises administering to the mammal in need thereof an anthelmintically effective amount of a pharmaceutical formulation of the invention.

Claims (33)

1. A pharmaceutically acceptable solid anthelmintic formulation comprising a combination of

a first active ingredient comprising particles of an avermectin spray granulated with polyethylene glycol around the particles;

a second active ingredient comprising an anthelmintic pyrimidine;

a third active ingredient comprising a hexahydropyrazinoisoquinoline; and

a fourth active ingredient comprising a benzimidazole or probenzimidazole,

wherein the polyethylene glycol coats the avermectin separating the avermectin from the second, third and fourth active ingredients.

2. The formulation of claim 1 , wherein the first active ingredient comprises ivermectin.

3. The formulation of claim 1 , comprising at least about 0.005% ivermectin.

4. The formulation of claim 1 , comprising about 0.012-5% ivermectin.

5. The formulation of claim 1 , comprising a tetrahydropyrimidine.

6. The formulation of claim 1 , wherein the second active ingredient comprises a pyrantel.

7. The formulation of claim 6 , wherein the pyrantel comprises pyrantel pamoate.

8. The formulation of claim 1 , comprising at least about 1.5% pyrantel.

9. The formulation of claim 1 , comprising about 11.2-33% pyrantel.

10. The formulation of claim 1 , wherein the third active ingredient comprises praziquantel.

11. The formulation of claim 1 , comprising at least about 2.0% praziquantel.

12. The formulation of claim 1 , comprising about 8.2-23% praziquantel.

13. The formulation of claim 1 , comprising at least about 25.3% fenbendazole.

14. The formulation of claim 1 , comprising about 30.0-45.0% fenbendazole.

15. The formulation of claim 1 , comprising at least about 15.2% febantel.

16. The formulation of claim 1 , comprising about 19.4-31.6% febantel.

17. The formulation of claim 2 , in a form that will remain stable and pharmaceutically active, in a solid form, for over one month.

18. The formulation of claim 17 , wherein there is an effective amount of polyethylene glycol to prevent the ivermectin from degrading sufficiently to eliminate its pharmaceutical effectiveness.

19. A method for forming an anthelmintic formulation comprising the steps of:

(A) preparing a combination of ivermectin and polyethylene glycol;

(B) spray granulating the combination to form granules, with the polyethylene glycol covering the ivermectin; and

(C) combining the granules with an additional active ingredient composition.

20. The method of claim 19 , wherein the additional active ingredient composition comprises pyrantel pamoate, praziquantel, and fenbendazole or febantel.

21. The method of claim 19 , wherein the formulation is pressed into a tablet or enclosed in a capsule and the ivermectin has been effectively isolated, so that the formulation will stay stable for over one month.

22. An anthelmintic formulation, which is formed by the method of claim 19 .

23. A method of controlling helminth infestation in animals, comprising the step of administering a pharmaceutically effective amount of the formulation of claim 2 to an animal in need thereof.

24. The method of claim 23 , wherein the animal is a dog or cat.

25. The method of claim 23 , wherein the administration comprises administering 5-7 μg/Kg body weight of the dog or cat.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2014
From: THE HARTZ MOUNTAIN CORPORATION
To: VIRBAC CORPORATION
Reel/Frame 033916/0585 →
ASSIGNMENT OF 50% UNDIVIDED INTEREST Recorded Aug 11, 2006
From: HARTZ MOUNTAIN CORPORATION, THE
To: VIRBAC CORPORATION
Reel/Frame 018105/0500 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2006
From: CHANELLE PHARMACEUTICALS MANUFACTURING LIMITED
To: HARTZ MOUNTAIN CORPORATION
Reel/Frame 018083/0265 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2004
From: COTTRELL, IAN W.; NANDY, ARIMA DAS; AHN, ALBERT; FISHER, RICHARD
To: HARTZ MOUNTAIN CORPORATION, THE; CHANELLE PHARMACEUTICALS MANUFACTURING LTD.
Reel/Frame 015154/0476 →
Continuity (2)
Continuation In Part 1063780700 · Aug 8, 2003
Related Publication 20050032719A1 · Feb 10, 2005